title: Recommended guidelines for the treatment of chemotherapy-induced diarrhea.
abstract: OBJECTIVE
  Management of chemotherapy-induced diarrhea (CID) has customarily involved symptomatic treatment with opioids in conjunction with supportive care. Alternatively, patients refractory to conventional therapy have been given octreotide, a somatostatin analogue. Although this agent has been effective against CID, no widely accepted treatment guidelines that incorporate its use currently exist. An expert multidisciplinary panel was convened to formulate clinical practice guidelines for the treatment of CID.
  
  
  METHODS
  The panel reviewed clinical data on the management of CID reported in the literature and analyzed currently available tools used to assess CID. Expert consensus was applied when published data were insufficient. Panel members also considered the effect of CID on quality of life and the cost-effectiveness and efficacy of different pharmacologic approaches. Effective resolution of CID and decreases in the need for supportive care or hospitalization were considered to be primary goals in the formulation of the guidelines.
  
  
  RESULTS
  The panel formulated suggested practice guidelines for the management of CID that detail recommendations for the assessment and evaluation of diarrhea and the sequence and duration of administration of specific pharmacologic agents.
  
  
  CONCLUSIONS
  The consensus of the panel was that standardized assessment and management of diarrhea is required to effectively control CID. The panel agreed that further data from a National Cancer Institute (NCI)-sponsored intergroup trial is required to determine the optimal dosage of octreotide and its cost in the treatment of cancer. The panel also agreed that further clinical research is warranted to address significant questions about the most effective way to assess and treat CID.
authors.affiliation: Montefiore Medical Center, Bronx, NY 10467, USA. wadler@jimmy.harvard.edu
authors.forename: S
authors.initials: S
authors.lastname: Wadler
authors.forename: A B
authors.initials: AB
authors.lastname: Benson
authors.forename: C
authors.initials: C
authors.lastname: Engelking
authors.forename: R
authors.initials: R
authors.lastname: Catalano
authors.forename: M
authors.initials: M
authors.lastname: Field
authors.forename: S M
authors.initials: SM
authors.lastname: Kornblau
authors.forename: E
authors.initials: E
authors.lastname: Mitchell
authors.forename: J
authors.initials: J
authors.lastname: Rubin
authors.forename: P
authors.initials: P
authors.lastname: Trotta
authors.forename: E
authors.initials: E
authors.lastname: Vokes
mesh_terms: D000970:Antineoplastic Agents / Q000009:adverse effects*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects; D002166:Camptothecin / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives; D003967:Diarrhea / Q000139:chemically induced* / Q000188:drug therapy / Q000628:therapy*; D005472:Fluorouracil / Q000008:administration & dosage / Q000009:adverse effects; D005765:Gastrointestinal Agents / Q000627:therapeutic use; D006801:Humans; D000077146:Irinotecan; D015282:Octreotide / Q000627:therapeutic use; D017410:Practice Guidelines as Topic
chemical_list: D000970:Antineoplastic Agents; D005765:Gastrointestinal Agents; D000077146:Irinotecan; D015282:Octreotide; D005472:Fluorouracil; D002166:Camptothecin